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Respiratory syncytial virus (RSV) is an important human respiratory pathogen, particularly in infants. Glycosaminoglycans
(GAGs) have been implicated in the initiation of RSV infection of cultured cells, but it is not clear what type of GAGs and GAG
components are involved, whether the important GAGs are on the virus or the cell, or what the magnitude is of their
contribution to infection. We constructed and rescued a recombinant green fluorescent protein (GFP)-expressing RSV (rgRSV)
and used this virus to develop a sensitive system to assess and quantify infection by flow cytometry. Evaluation of a panel
of mutant Chinese hamster ovary cell lines that are genetically deficient in various aspects of GAG synthesis showed that
infection was reduced up to 80% depending on the type of GAG deficiency. Enzymatic removal of heparan sulfate and/or
chondroitin sulfate from the surface of HEp-2 cells also reduced infection, and the removal of both reduced infection even
further. Blocking experiments in which RSV was preincubated with various soluble GAGs revealed the relative blocking order
of: heparin . heparan sulfate . chondroitin sulfate B. Iduronic acid is a component common to these GAGs. GAGs that do
not contain iduronic acid, namely, chondroitin sulfate A and C and hyaluronic acid, did not inhibit infection. A role for iduronic
acid-containing GAGs in RSV infection was confirmed by the ability of basic fibroblast growth factor to block infection,
because basic fibroblast growth factor binds to GAGs containing iduronic acid. Pretreatment of cells with protamine sulfate,
which binds and blocks GAGs, also reduced infection. In these examples, infection was reduced by pretreatment of the virus
with soluble GAGs, pretreatment of the cells with GAG-binding molecules, pretreatment of the cells with GAG-destroying
enzymes or in cells genetically deficient in GAGs. These results establish that the GAGs involved in RSV infection are present
on the cell rather than on the virus particle. Thus, the presence of cell surface GAGs containing iduronic acid, like heparan
sulfate and chondroitin sulfate B, is required for efficient RSV infection in cell culture. © 2000 Academic PressINTRODUCTION
Respiratory syncytial virus (RSV) belongs to the Pneu-
movirus genus of the Paramyxoviridae family. It causes
severe pneumonia and bronchiolitis in some infants, mild
upper respiratory tract infections in persons of all ages,
and serious disease in some normal adults, elderly per-
sons, and immunocompromised individuals. In immuno-
competent patients, RSV remains limited to the respira-
tory tract. In cell culture, however, RSV infects many cell
lines, including human epidermoid HEp-2 and HeLa
cells, monkey kidney cells (Vero), and rodent cells such
as Chinese hamster ovary (CHO) and mouse L cells. In
many cell lines, within 48 h of inoculation, RSV induces
characteristic cytopathic effects, including syncytia, loss
of cell integrity, and spicule-like structures on the cell
surface (Walter and Downing, 1993).
The virus particle is composed of a nucleocapsid, a
matrix protein, M1, and an envelope. The nucleocapsid
contains the negative-strand RNA genome wrapped in a
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264helical conformation by the nucleocapsid (N) protein and
associated with three proteins required for transcription
and replication: the phosphoprotein (P), the large (L)
protein, and the M2-open reading frame 1 (M2-1) protein.
The envelope is derived from the host cell, and it con-
tains a lipid bilayer membrane and the three viral trans-
membrane glycoproteins: the glycoprotein (G), the fusion
(F) protein, and the small hydrophobic (SH) protein. The
G protein has been identified as the attachment protein
(Levine et al., 1987). The RSV G protein is an unusual
attachment protein with mucin-like features, including a
high content of O-linked sugars, and it is distinct from the
attachment protein of other paramyxoviruses. The F pro-
tein is required for virus-to-cell membrane fusion during
the initiation of infection and cell-to-cell fusion during
syncytia formation (Walsh and Hruska, 1983). Expression
of the F protein, alone, in cells causes some fusion, but
coexpression of either the G or SH proteins, and partic-
ularly coexpression of both, enhances fusion (Pastey and
Samal, 1997; Heminway et al., 1994). Interestingly, neither
G nor SH is absolutely required for infection, because
RSV lacking both genes is able to replicate in Vero cells,
although it is seriously impaired in animals (Karron et al.,
265GLYCOSAMINOGLYCANS IN RSV INFECTION1997). There also are two nonstructural proteins encoded
by the RSV genome: NS1 and NS2. It is not clear whether
M2-2 is a structural or nonstructural protein.
GAGs are unbranched polymers of repeating disac-
charide units that consist of either glucuronic acid or its
epimer, iduronic acid, linked to glucosamine or galac-
tosamine, with further modifications such as sulfation at
various positions. They are found on the outer face of the
cell membrane, in intracellular vesicles, and in the ex-
tracellular matrix. GAGs are expressed at varying levels
on most animal tissues. Of the seven types of GAGs, five
might be physiologically relevant for RSV infection be-
cause they are expressed on the surface of most cells:
heparan sulfate (HS), chondroitin sulfate A (chondroitin-
4-sulfate), B (dermatan sulfate), and C (chondroitin-6-
sulfate) (described herein as CS-A, CS-B, and CS-C,
respectively) and hyaluronic acid (HA). The other two
types, heparin and keratan sulfate, are found only in
specialized cells, a subset of mast cells and keratino-
cytes, respectively, but not on any structural lung cells
(Schmid et al., 1982).
All of the cell surface GAGs are covalently linked to
transmembrane “core” proteins, except for HA, which is
secreted, although some HA does bind to the cell sur-
face via its receptor, CD44 (Knudson and Knudson, 1993;
Underhill, 1992). The GAGs that are linked to core pro-
teins are attached covalently via an O-glycosidic linkage
to Ser within the signature Ser-Gly dipeptide preceded
by acidic amino acids, but not all such sites are modified
(Esko and Zhang, 1996). The various GAGs are distin-
guished both by the composition of their disaccharide
subunits and by postsynthetic modifications. The com-
position of the five GAGs described in the present report
are as follows: HS consists of glucuronic acid or iduronic
acid linked to N-acetylglucosamine; CS-A and CS-C con-
tain glucuronic acid linked to N-acetylgalactosamine
modified by sulfation on C4 or C6, respectively; CS-B
contains iduronic acid linked to N-acetylgalactosamine
modified by sulfation on C4; and HA contains glucuronic
acid linked to N-acetylglucosamine but is not sulfated
and, as mentioned above, is not covalently linked to a
protein. Some GAG chains occur in copolymer forms, For
example, CS-A is often present on the same chain as
CS-B and/or CS-C, such that most of the CS-B is present
in copolymers.
Biosynthesis of cell surface GAGs involves several
steps: (1) synthesis of the core protein and translocation
and anchoring in the ER, (2) transfer of xylose from
UDP-xylose to the hydroxyl group of serine followed by
the addition of two galactose residues to complete the
trihexose linkage region, (3) sequential addition of glu-
curonic acid and aminosugars, (4) N-deacetylation and
N-sulfation, and (5) epimerization of some of the glucu-
ronic acid at the C5 position, generating iduronic acid, by
the action of uronosyl 5-epimerase (Lindahl et al., 1986;
Lindahl, 1990a). This step requires N-sulfation of glu-cosamine (Backstrom et al., 1979) or C4 sulfation of
galactosamine (Silbert et al., 1991). Inhibition of sulfation
at these positions has been shown to reduce the idu-
ronic acid content (Backstrom et al., 1979; Silbert et al.,
1991; Greve et al., 1988). (6) Other modifications include
sulfation at position C6, C3, or C2.
Heparin was the first GAG found to affect virus repli-
cation, when it was shown to limit the growth of herpes
simplex virus (HSV) (Nahmias and Kibrick, 1964). Later, it
was shown that herpes virus interacts with cell surface
HS to initiate infection (WuDunn and Spear, 1989; Spear
et al., 1992; Shieh et al., 1992). Other viruses have also
been found to interact with GAGs, including Sindbis virus
(Klimstra et al., 1998; Byrnes and Griffin, 1998), foot-and-
mouth disease virus (Mondor et al., 1998), human immu-
nodeficiency virus type 1 (Jackson et al., 1996), vaccinia
virus (Hsiao et al., 1999; Hsiao et al., 1998), and dengue
virus (Chen et al., 1997). GAG involvement has also been
reported for RSV infection, although there is controversy
as to whether the GAGs are on the virus envelope (Bour-
geois et al., 1998) or on the target cell (Krusat and
Streckert, 1997).
Insertion of the GFP marker gene into the genome of a
virus can serve as a useful tracer for following virus
infection (Baulcombe et al., 1995). By constructing and
using rgRSV, we have been able to quantitatively study
the role of GAGs in mediating RSV infection of cultured
cells. We examined cells in which particular GAGs have
been removed by mutation or enzymatic digestion and
studied purified GAGs for their ability to block infection.
We found that both cell surface HS and CS-B are involved
in infection of cultured cells and that binding activity
correlates with the presence of iduronic acid in the GAG
disaccharide.
RESULTS
rgRSV
We inserted the GFP gene before the first gene in a
full-length cDNA copy of the RSV genome along with the
proper gene start and gene end signals. In this construct,
the GFP gene flanked by RSV gene-start and gene-stop
signals was inserted into a naturally occurring BstXI site
(RSV antigenome positions 35–46) that lies at the bound-
ary between the 44-nucleotide leader region and the
NS1 gene (Fig. 1A). Insertion of the GFP gene cassette
regenerated the leader region intact, placed the GFP
gene as the first gene, inserted a 10-nucleotide inter-
genic, and otherwise left the gene order intact. The
recombinant rgRSV virus thus expressed one additional
mRNA, namely GFP, compared with wild-type RSV. This
plasmid was transfected into HEp-2 cells along with four
other plasmids encoding the N, P, L, and M2-1 proteins to
support RSV transcription and replication, as previously
described (Collins et al., 1995). The cells were also in-
fected with vaccinia virus, MVA-T7, to provide T7 RNA
t
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mids (Wyatt et al., 1995). Successfully transfected/in-
fected cells became green as viewed through a fluores-
FIG. 1. (A) Construction of rgRSV, a recombinant RSV expressing th
he leader–NS1–NS2–N region of the wild-type RSV antigenome, togeth
ccording to the complete antigenome sequence, and the naturally occ
rgRSV, where the GFP expression cassette was inserted into the BstXI
HEp-2 cells infected with rgRSV. After inoculation, cells were incubat
Individual infected cells, as well as syncytia, are present.cence microscope between 24 and 48 h posttransfec-
tion. The supernatant medium was harvested and usedto inoculate HEp-2 cells in several rounds of amplifica-
tion to prepare a stock of rgRSV. HEp-2 cells infected
with rgRSV are readily detected by fluorescence micros-
gene as the first, promoter-proximal gene. The upper diagram shows
the sequence of the leader–NS1 junction. The sequence is numbered
BstXI site is underlined. The lower diagram shows the same region in
he sequence of the leader–GFP and GFP–NS1 junctions is shown. (B)
48 h at 37°C and observed in an inverted fluorescence microscope.e GFP
er with
urring
site. Tcopy by 20 h postinoculation. Figure 1B shows cells at
48 h postinoculation.
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267GLYCOSAMINOGLYCANS IN RSV INFECTIONInfection of GAG-deficient CHO cell lines
If cell surface GAGs are involved in RSV infection, cell
lines deficient in individual enzymes needed to produce
the various GAGs might differ in their susceptibility to
rgRSV infection. A series of such mutant CHO cell lines
have previously been isolated after mutagenesis of the
parental CHO K1, and their defects have been character-
ized (Esko and Raetz, 1978). They were first used to study
the role of GAGs in virus infection by WuDunn and Spear
(1989) in an examination of HSV infection. We tested
CHO K1 and several of these mutant cell lines for their
sensitivity to rgRSV infection. Cells were inoculated with
rgRSV and incubated at 37°C for 36 h. The appearance of
GFP in CHO cells is delayed compared with HEp-2 cells,
requiring a longer incubation before analysis. The per-
centage of infected cells for each CHO cell line was
determined by flow cytometry (Fig. 2).
The mutant CHO cell line A-745 is deficient in xylosyl-
transferase, the enzyme required for the first sugar trans-
fer reaction in GAG formation. Less than 7% of the enzy-
matic activity remains in these cells. As a result of this
deficiency, A-745 does not express HS or CS (Esko et al.,
1985). CHO A-745 cells were five times less susceptible
to rgRSV infection than CHO K1 (Fig. 2). Another mutant
cell line, CHO pgsB-761, is deficient (less than 2% en-
zyme activity remaining) in galactosyltransferase I (UDP-
D-galactose:xylose b-1,4-D-galactosyltransferase), result-
ing in deficiencies in both CS and HS expression (Esko
et al., 1987). These cells are three times less susceptible
to rgRSV infection than CHO K1. A third cell line, CHO
pgsD-677, is defective in both N-acetylglucosaminyl-
transferase and glucuronosyltransferase, by 50- and
1000-fold, respectively (Lidholt et al., 1992). Both of these
enzymes are required for the biosynthesis of HS. Inter-
FIG. 2. Sensitivity of proteoglycan synthesis-deficient CHO cell lines
to rgRSV. Each cell line was inoculated with the same amount of rgRSV
and analyzed by flow cytometry at 36 h postinoculation. Percentages of
infected cells relative to K1 are noted above each bar.estingly, pgsD-677 makes approximately three times
more total CS than CHO K1 (Esko et al., 1988). Theseells are approximately three times less susceptible to
gRSV infection.
reatment of cells with GAG-specific enzymes
educes infection
To confirm the results obtained from the mutant CHO
ell lines and to attempt to identify the GAG(s) that
ediates RSV infection, we used GAG-specific enzymes
o remove GAGs from the cell surface and tested the
bility of rgRSV to infect these cells. HEp-2 monolayers
ere treated with enzymes at 37°C for 3 h with occa-
ional shaking, washed, and then inoculated with rgRSV
multiplicity of infection (m.o.i.) of 1] for 1 h at 37°C,
ncubated at 37°C for 24 h in complete medium, and
nalyzed by flow cytometry (Fig. 3).
All enzymatic treatments reduced the susceptibility of
Ep-2 cells to rgRSV infection, indicating that cellular
AGs are involved in rgRSV infection. Only HA lyase
Streptomyces hyalurolyticus) had no effect (Fig. 3A, sam-
le 6). This enzyme specifically cleaves HA at b-GlcNAc-
[1–4]glycosidic bonds (Ohya and Kaneko, 1970), and its
lack of effect suggests that HA is not an important GAG
for rgRSV infection.
Several of the other enzymes used have overlapping
specificities, making it difficult to determine with cer-
tainty the responsible GAG from this experiment. For
instance, sheep testicular hyaluronidase type III (Fig. 3A,
sample 7) randomly cleaves b-N-acetyl-hexosamine-[1–
4]glycosidic bonds in HA, CS-A, CS-B, CS-C, and their
copolymers (Borders and Raftery, 1968). Chondroitinase
AC (sample 3) also reduced infection, but in addition to
removing CS-A and CS-C, this enzyme also releases
CS-B if it is in a copolymer with either CS-A or CS-C
(Yamagata et al., 1968; Suzuki et al., 1968). Therefore, the
reduction in infection caused by chondroitinase AC could
be due to the release of CS-A, B, or C from the cell
surface.
CS-B lyase cleaves CS-B at its b-D-galactosamine-L-
iduronic acid linkage (Michelacci and Dietrich, 1975),
and heparitinase (Flavobacterium heparinum) cleaves
HS in poorly sulfated regions (Lohse and Linhardt, 1992)
(Fig. 3A, sample 5). CS-B lyase reduced rgRSV infection
to 55% (sample 2), whereas heparitinase reduced infec-
tion to 37% (sample 5). These results suggest that both
CS-B and HS (Godavarti and Sasisekharan, 1998; Fors-
berg et al., 1999) are involved in initiating rgRSV infection.
Heparinase I cleaves only heparin and HS and reduced
infection to 60% (sample 4). Because heparin is not found
on the surface of cells, this effect must be due to release
of HS, consistent with the heparitinase results.
To confirm that both CS-B and HS are involved in
rgRSV infection and that heparitinase and CS-B lyase are
removing separate entities rather than copolymers, we
compared the effect of each enzyme alone to a combi-
nation of the two. Figure 3B shows 53% infection (sample
268 HALLAK ET AL.2) in CS-B lyase-treated cells, 35% infection (sample 3) in
heparitinase-treated cells, and 14% infection (sample 4)
when both enzymes were used together. This result
confirms the involvement of both HS and CS-B in medi-
ating rgRSV infection. The finding that the combined
effect of the two lyases was greater than either alone
indicated that both molecules are involved in RSV infec-
tion but that the presence of one could partially, but not
completely, substitute for the other.
Soluble heparin and HS block infection
FIG. 3. Treatment of HEp-2 cells with GAG-specific enzymes before
inoculation with rgRSV. The 70% confluent cells in 12-well plates were
washed and covered with 250 ml of OptiMEM I containing the minimal
number of enzyme units that gave the highest RSV reduction at 37°C for
3 h (data not shown). Cells were analyzed by flow cytometry at 24 h
postinoculation. (A) Each column represents treatment with a different
enzyme in the presence of 10% FBS to block the activity of possible
contaminating proteases: (1) untreated cells, (2) chondroitin sulfate B
lyase (20 mIU/ml), (3) chondoitinase AC (0. 3 mIU/ml), (4) heparinase I
(3.3 mIU/ml), (5) heparitinase (3.3 mIU/ml), (6) bacterial HA lyase (20
Sigma units/ml), and (7) testicular HA lyase (20 Sigma units/ml). (B)
Pretreatment of HEp-2 cells with the same concentration of enzymes as
in A: (1) untreated cells, (2) chondroitin sulfate B lyase, (3) heparitinase,
or (4) both chondroitin sulfate B lyase and heparitinase. Percentage of
infected cells relative to untreated cells are noted above each bar.If enzymatic removal of HS from the HEp-2 cell surface
reduced rgRSV infection by removing an attachment sitefor rgRSV, then soluble HS should be able to bind to the
virus and block infection. In these experiments, we also
tested heparin, because it has the same carbohydrate
composition as HS except that it contains more iduronic
acid, the epimerized form of glucuronic acid; is more
highly sulfated; and is less acetylated (Lindahl et al.,
1989; Lindahl, 1990b). Bovine lung heparin and bovine
kidney HS were serially diluted in medium, rgRSV was
added, and the mixture was incubated at 37°C for 1 h.
The mixture was then used to inoculate HEp-2 cells.
After removing the inoculum, washing the cells, and
adding fresh medium, the plates were incubated at 37°C.
After 24 h, the cells were analyzed by flow cytometry (Fig.
4A). Heparin strongly inhibited rgRSV infection, but bo-
vine kidney HS did not have an effect at any of the
concentrations shown. The poor blocking effect of bo-
vine kidney HS despite the reduction in infection caused
FIG. 4. Effects of soluble heparin or HS on rgRSV infectivity. Dilutions
of bovine lung heparin or HS were prepared and mixed with fixed
amounts of rgRSV and incubated 30 min at 37°C. The mixtures were
replaced with fresh medium and assessed by flow cytometry at 24 h
postinoculation. (A) Bovine kidney HS compared with heparin. (B)
Bovine kidney HS compared with bovine and porcine intestinal HS.
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269GLYCOSAMINOGLYCANS IN RSV INFECTIONby removing cell surface HS (Fig. 3) is puzzling but has
been found previously for RSV (Bougeois et al., 1998) and
Sindbis virus (Byrnes and Griffin, 1998) infections. How-
ever, we also tested HS from bovine and porcine intes-
tinal mucosa for their ability to block rgRSV infection.
Unlike the HS from bovine kidney, the HS from both
intestinal sources blocked rgRSV infection (Fig. 4B). The
difference in activity of HS from different tissues might be
due to the degree of sulfation and/or the iduronic acid
content, even though the basic building blocks, alternat-
ing hexuronic acid (glucuronic or iduronic) and D-glu-
osamine (N-acetylated or N-sulfated), remain the same
Toida et al., 1997; Tekotte et al., 1994). The vendor
eports their total sulfation as 5.62%, 10.2%, and 5.79% for
ovine kidney, bovine intestinal, and porcine intestinal
S, respectively, suggesting that total sulfate content is
ot responsible for the difference in inhibition.
ffects of soluble CS-A, B, and C and HA on infection
In similar blocking experiments, we tested the effect of
reincubation of soluble CS-A, B, and C with rgRSV (Fig.
). Only CS-B reduced rgRSV infectivity, suggesting that it
ontains an important component not present in the
ther two. CS-A and CS-B have the same structure and
osition (C4) of sulfation, differing only in that CS-A
ontains glucuronic acid, whereas CS-B contains its
pimer, iduronic acid. CS-B from human milk has been
hown by others to have an inhibitory effect on RSV
nfection (Portelli et al., 1998).
Preincubation of rgRSV with dilutions of HA before
noculation of cells did not inhibit rgRSV infection (Fig.
B). The slight reduction seen at high concentrations
ay be due to the viscosity of HA in aqueous solution,
hich might have retarded diffusion. This is consistent
ith the results in Fig. 3, where enzymatic digestion of
A with bacterial HA lyase did not affect rgRSV infection.
duronic acid is a critical GAG component for
ediating infection
In the work described above, three GAGs, namely,
eparin, HS, and CS-B, inhibited RSV infection, whereas
S-A, CS-C, and HA had no effect. Interestingly, heparin,
S, and CS-B all contain iduronic acid, whereas CS-A,
S-C, and HA do not (Table 1).
To confirm the importance of iduronic acid in rgRSV
nfection, we tested the effect of pretreatment of virus or
ells with basic fibroblast growth factor (bFGF), which
inds specifically to GAGs containing iduronic acid
Chintala et al., 1994; Westergren-Thorsson et al., 1993;
urnbull et al., 1992). First, virus was preincubated with
FGF, and the mixture was used to inoculate cells. Cells
ere harvested 24 h later and analyzed by flow cytom-
try. As shown in Fig. 6A, bFGF did inhibit infection. To
etermine whether this effect was due to bFGF binding
o the cells or to the virus, we treated cell monolayersith bFGF (10 mg/ml) for 1 h before, during, or after rgRSV
inoculation. As shown in Fig. 6B, bFGF did not affect RSV
replication when it was added after inoculation, indicat-
ing that its inhibitory activity is not due to an alteration in
the metabolic state of the cells. However, bFGF did block
infection when it was added before and washed out, or
with the virus, indicating that bFGF acted on the cell
surface to interfere with an initial step of binding/entry of
RSV.
Effect of protamine sulfate on infection
Protamine sulfate is highly basic polyanion used clin-
ically as an antagonist for heparin. It binds to heparin,
reversing its anticoagulant properties (Byun et al., 1999).
In addition to neutralizing heparin, protamine sulfate can
FIG. 5. Effects of preincubation with soluble CS-A, CS-B, CS-C, or HA
on rgRSV infection. Serial dilutions of each GAG were prepared and
mixed with equal amounts of rgRSV. The mixture was incubated 30 min
at 37°C and then used to inoculate HEp-2 cells for 2 h. The cells were
incubated 24 h, and the percentage of infected cells was quantified by
flow cytometry. (A) Effects of CS-A, CS-B, and CS-C on rgRSV infectivity.
(B) Effects of HA on rgRSV infectivity.neutralize HS (Hubbard and Jennings, 1985) and CS-B
(Sie et al., 1989). If HS and CS-B on the cell surface are
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270 HALLAK ET AL.important in initiating rgRSV infection, as indicated by the
experiments described, protamine pretreatment of the
cells should bind and block these GAGs, which in turn
should reduce the efficiency of infection. Protamine pre-
treatment of the cells did partially block infection (Fig. 7).
In contrast, protamine had no effect on infection when
incubated with the virus for 1 h and then diluted fivefold,
along with the virus, before inoculation, nor did prota-
mine have an effect when added 1 h after inoculation.
Conversely, pretreatment of cells with CS-B or heparin
did not inhibit infection, whereas preincubation with
rgRSV did. These results are consistent with an impor-
tant role for cell-associated HS and CS-B in RSV infec-
tion.
DISCUSSION
Efficient infection of cultured cells by rgRSV, and
wtRSV by extension, requires GAGs, most likely as an
initial binding step. Four lines of evidence support this
conclusion: (1) reduced infection of GAG-deficient cell
lines by up to 80%, depending on the defective enzyme
involved; (2) neutralization of RSV by soluble GAGs; (3)
reduction in RSV infection in cells pretreated with prota-
mine, which neutralizes GAGs (Byun et al., 1999), or
retreatment with bFGF, which binds iduronic acid-con-
aining GAGs (Sie et al., 1989; Hubbard and Jennings,
985); and (4) reduced infection after enzymatic removal
f cellular GAGs. Enzymatic removal of either HS or CS-B
ecreases infection efficiency, and removal of both fur-
her decreases infection, indicating that RSV uses both of
hese GAGs for efficient infection of host cells.
The surface of most cells is decorated with several
AG types, including HS, CS-A, CS-B, CS-C, and HA
TABLE 1
Iduronic Acid Presence in GAG Polymers and Their IC50 Values
a
GAG Iduronic acid IC50 (mg/ml)
Heparin 1b 1.0
HS 1c 12.5d
CS-A 2e .400.0
CS-B 1 f 200.0
CS-C 2e .400.0
HA 2e .400.0
a Inhibitory concentration of each GAG that prevents infection of 50%
f the HEP-2 cells. Data from Figs. 4 and 5.
b Lindahl et al., 1986; Perlin, 1979; 1 represents the presence of
iduronic acid.
c Maccarana et al., 1996.
d Bovine intestine HS data from Fig. 4B.
e Champe and Harvey, 1987; 2 represents the absence of iduronic
acid.
f Bossennec et al., 1990.ound to CD44. In our blocking experiments, soluble
eparin had the strongest blocking effect on RSV infec-
w
Cion (Table 1), and treatment of cells with heparinase
educed infection. Heparin, a molecule secreted by mast
ells, is a convenient experimental surrogate for GAGs
ut is not itself found on the cell surface and therefore
ould not be involved in virus entry. However, heparin
eleased by mast cells during RSV infection might have
ntiviral activity. Both soluble CS-B and HS (from intesti-
al sources) were able to block infection. Both HS
Nackaerts et al., 1997; Lories et al., 1987) and CS-B (van
uppevelt et al., 1984, 1985) are found in the lungs with
ifferent distribution patterns. It is interesting to note that
here is a switch from CS-B to CS-C in the lungs with
ncreasing age (Schmid et al., 1982). This switch seems
o correlate roughly with the prevalence of severe RSV
espiratory tract infection in infants rather than adults.
Several studies on the role of cell surface proteogly-
ans in viral infection have reported the effectiveness of
eparinases and the ability of soluble heparin to block
nfection but could not explain the apparent discrepancy
hat soluble HS does not block infection (Bourgeois et al.,
FIG. 6. Effect of bFGF on rgRSV infection. Equal amounts of rgRSV
were mixed with serial dilutions of bFGF. (A) HEp-2 cells were inocu-
lated with the mixtures and incubated 24 h before assessment of
infection by flow cytometry. (B) HEp-2 cells were incubated with bFGF
(10 mg/ml) 1 h before inoculation or during the 1-h adsorption period or
h postinoculation. After each exposure, bFGF was removed and cells
ere washed three times before the addition of virus or fresh medium.
ells were incubated for 24 h before analysis.
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271GLYCOSAMINOGLYCANS IN RSV INFECTION1998; Krusat and Streckert, 1997; Byrnes and Griffin,
1998). We obtained the same results when using bovine
kidney HS, but surprisingly we found that purified HS
from intestinal sources has strong inhibitory effects on
RSV infection. It would be interesting to determine the
structural differences between the HS from these two
sources, because this might identify structural GAG re-
quirements for binding RSV.
Soluble CS-A and CS-C and HA were not inhibitory.
Nevertheless, chondroitinase AC treatment of cells be-
fore inoculation reduced the number of infected cells.
These findings are reconciled by the fact that most, if not
all, of the CS-B on the cell surface is in a copolymer form
with CS-A and CS-C (Karamanos et al., 1995). Cleavage
within a CS-A or CS-C region would release the entire
chain, including the CS-B components. CS-B lyase might
also remove the CS-A and CS-C in copolymers with
CS-B. However, among the soluble chondroitin sulfates,
only CS-B inhibited rgRSV infection, indicating that CS-B
is the only one of these molecules that binds RSV.
This is the first report to identify iduronic acid as an
important GAG component in initiation of viral infection.
Unlike glucuronic acid or other GAG subunits, iduronic
acid allows greater rotation and flexibility of the GAG
chains required for biological functions and binding (Lin-
hardt et al., 1991; Casu et al., 1988). For instance, (1)
ynthetically modified HS that contains a higher amount
f iduronic acid than glucuronic acid exhibits higher
inding activity for bFGF (Kovensky et al., 1999); (2) the
eparin pentasaccharide that binds to antithrombin III
ontains iduronic acid (Piepkorn et al., 1978; Jacobsson
t al., 1986); (3) only iduronic acid-containing GAGs in-
ibit the proliferation of fibroblasts (Westergren-Thorsson
FIG. 7. The effect of protamine, HS, and CS-B on rgRSV infection
elative to the time of inoculation. HEp-2 cells were treated with pro-
amine (200 mg/ml) heparin (10 mg/ml) or CS-B (500 mg/ml) for 1 h, the
edium removed and rinsed once with PBS before inoculation (cell).
gRSV was pretreated with these agents and then diluted five times
efore inoculation (virus), or the cells were incubated for 1 h with the
gents after inoculation (post). Cells were incubated 24 h before as-
essing the level of infection by flow cytometry. Medium was used as
control.t al., 1993, 1991); and (4) binding of heavy metal ions to
AGs is dependent on the presence of iduronic acidWhitfield et al., 1992). In this report, we have shown that
nly iduronic acid-containing soluble GAGs, heparin, HS,
nd CS-B, reduced RSV infection. Consistent with the
ole of iduronic acid in RSV binding, treatment of cells
ith bFGF, which binds GAGs containing iduronic acid,
nhibited RSV infection.
Although iduronic acid seems to be a requirement for
SV binding, it is clearly not the only necessary GAG
omponent. The amount of each GAG needed to inhibit
gRSV infection by 50% varied, from 1 mg/ml for heparin
to 12.5 mg/ml for some HS to 200 mg/ml for CS-B (Table
). It is likely that other aspects of these GAGs, such as
he type of aminosugar (i.e., glucosamine versus galac-
osamine) or sulfation, are important for binding.
Krusat et al. (1997) have shown an interaction between
the RSV attachment protein G and heparin by affinity
chromatography. The G protein contains a positively
charged lysine-rich region (Langedijk et al., 1996). Pep-
tides from this region of both RSV subgroups bind to
heparin, and pretreatment of cells with these peptides
inhibits infection (Feldman et al., 1999). It seems likely,
then, that the virion G proteins binds to cell surface
GAGs.
Bourgeois et al. (1998) concluded that the RSV G
rotein contains a heparin-like structure (not a heparin-
inding structure) responsible for RSV-cell attachment.
heir conclusion was based on the idea that one or more
f the many O-linked carbohydrates on the G protein
ight be a GAG chain, and this is the GAG that enhances
SV infection. This possibility is unlikely because half of
he reported RSV G protein sequences lack the Ser-Gly
ignal necessary for GAG addition (Chopra et al., 1985).
Furthermore, only a fraction of the Ser-Gly sequences in
known proteoglycan core proteins are used for GAG
linkage (Kokenyesi and Bernfield, 1994). Other require-
ments for the utilization of the Ser-Gly dipeptide in GAG
linkage include the presence of acidic amino acids N
terminal to the Ser-Gly dipeptide (Zhang and Esko, 1994;
Bourdon et al., 1987) and repetition of this dipeptide
(Zhang et al., 1995). These requirements are not found in
the G protein. Therefore, it is unlikely that any GAG is
linked to the RSV G protein.
Our experiments with the GAG-deficient CHO cell
lines, in which defects in GAG assembly decreased
infection by as much as 80%, are very strong evidence
that the important GAGs are on the cell. This finding is
supported by reduced efficiency of RSV infection of cells
that have been pretreated with protamine. Because pro-
tamine neutralizes GAGs (Byun et al., 1999; Sie et al.,
1989; Hubbard and Jennings, 1985), the important GAGs
must be on the cell.
Like Krusat et al. (1997), we found that heparin blocks
RSV infection only when it is present during inoculation.
We found that pretreatment of cells with heparin or CS-B
or the addition of these reagents after inoculation did not
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272 HALLAK ET AL.affect infection. These results again indicate that the
virus binds cell surface GAGs to initiate infection.
Finally, we attempted to label the RSV G protein with
35SO4, a specific method to label GAGs, because they are
the major sulfated biomolecules. In two attempts, we
purified virus from cells labeled with 35SO4 for 24 h but
were unable to detect any 35S-labeled viral proteins or
ellular proteoglycans in the virions (data not presented).
GAG–RSV interaction on the cell surface is necessary
or 80% of RSV infection (Fig. 2). It is possible that HS
nd/or CS-B is a specific receptor for RSV, as recently
hown for a particular sulfated form of HS and HSV type
(Shukla et al., 1999). It is also possible that this inter-
ction is not the only interaction between RSV and the
ell surface, because rgRSV still infects 20% of CHO
-745 cells despite their severe GAG deficiency. Perhaps
he G protein has a second binding step that can pro-
eed at 20% efficiency without GAG binding. It may be
hat during infection, RSV binds to HS and/or CS-B
hains on the cell surface. The bound RSV is thereby
oncentrated on the plasma membrane, allowing it to
earch more efficiently for its receptor in two dimensions
ather than in three. The presence of a highly conserved
egion in the G protein has been suggested to be the
inding site that might interact with a cellular receptor
Johnson et al., 1987).
Others have reported the propagation of RSV lacking
he G and SH genes (Karron et al., 1997). This evidence
ould suggest that the only remaining viral glycoprotein,
, has the ability to bind to cells. In wtRSV, perhaps the G
rotein binds to cell surface GAGs, and then the F pro-
ein binds to a receptor before initiating fusion.
MATERIALS AND METHODS
onstruction and rescue of rgRSV
The Green Lantern Protein (Life Technologies, Grand
sland, NY) gene was amplified by PCR with Vent poly-
erase, using a positive sense primer (59-CTGCA-
AACC AAAAAAATGG GGCAAATACC CGGGTCACCA
TGAGCAAGGG CGAGGAACTG) that contained a BstXI
ite (italics) and the RSV gene start sequence (under-
ined) followed by the initial nucleotides from the GFP
RF (bold) and a negative sense primer (59-CTGCA-
AACC ATTTTTTTGG TTTTTTATTA ACTCTCCCGG
GTACCGCTCA CTTGTACAGC TCGTCCATGC C) that con-
ained a BstXI site (underlined), the RSV gene end se-
uence (italics), and the end of the GFP ORF (bold). The
stXI sequences in these primers matched the BstXI site
n the RSV genome leader. Because the BstXI site is not
nique in the full-length RSV cDNA sequence, the PCR
ragment was inserted into the leader of the partial RSV
lasmid D13, containing the leader, NS1, NS2, N, P, M,
nd SH genes, to generate plasmid MP91. The MP91
atII/AvrII fragment containing the GFP gene was then
sed to replace that fragment in the full-length genome
c
plone D46 to generate MP125. This plasmid was used to
escue virus (Collins et al., 1995) by cotransfecting HEp-2
ells with pTM-1 plasmids expressing the RSV N, P, L,
nd M2-1 proteins from a T7 promoter and infecting with
he recombinant vaccinia virus MVA-T7 (Wyatt et al.,
995) to provide the T7 polymerase.
ells and media
HEp-2 cells were maintained in OptiMEM I (GIBCO
RL, Grand Island, NY) medium supplemented with 2%
BS. Mutant CHO cell lines lacking different enzymatic
ctivities required for GAG production or sulfation were
indly provided by Jeff Esko (Department of Biochemistry,
chools of Medicine and Dentistry, University of Ala-
ama, Birmingham, AL). CHO cells were maintained in
MEM/F-12 (GIBCO BRL), 10% FBS.
nfection experiments
Stocks of rgRSV were prepared in HEp-2 cells by
noculation with an m.o.i. of 0.3, incubating for 3 days at
7°C and 5% CO2, harvesting by scraping cells from the
onolayer with a rubber policeman, vortexing, and cen-
rifuging at 1000 g for 10 min to remove debris. Stocks
ere aliquoted and stored at 270°C.
For experiments, cells were seeded onto 12-well tis-
ue culture plates in the medium described above and
ncubated overnight at 37°C and 5% CO2. The 60–70%
confluent monolayers were washed once with Dulbec-
co’s PBS (GIBCO BRL) and inoculated with rgRSV at an
approximate m.o.i. of 1. The virus stock was diluted in
OptiMEM I when required. Plates were incubated to
allow virus binding at 37°C for 2 h unless otherwise
noted. The inoculum was removed, and cells were
washed once with PBS; then fresh medium was added,
and the plates were reincubated at 37°C for 24 or 36 h
for HEp-2 and CHO cells, respectively.
Flow cytometry and cell count
rgRSV-infected cells were washed with PBS and de-
tached from tissue culture dishes using either Versene
1:5000 (GIBCO BRL) or 13 Trypsin-EDTA (GIBCO BRL).
Cells were pipetted up and down several times to gen-
erate a single-cell suspension. Cells were spun at 2000
rpm for 5 min in a Brinkmann Instruments (Westbury, NY)
Eppendorf Desktop Microfuge 5415. The supernatant
was removed, and cells were suspended in 300 ml of
PBS and fixed by the addition of 600 ml of 3% parafor-
maldehyde solution (15 g paraformaldehyde, 28 mM
KH2PO4, 36 mM Na2HPO4, and H2O to 500 ml; heated to
0°C until dissolved, filtered, and stored at 4°C). Sam-
les were vortexed briefly before loading them in the flow
ytometry system (Ortho Cytoronabsolute; Ortho Diag-
ostic Systems, Raritan, NJ). The fluorescence of 5000
ells for each sample were measured and plotted as a
ercentage of infected cells.
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All soluble GAGs, GAG-specific enzymes, bFGF, and
protamine were obtained from Sigma Chemical Co. (St.
Louis, MO): bovine lung heparin (H-9133), porcine intes-
tinal mucosa HS (H-9902), bovine intestinal mucosa HS
(H-5393), bovine kidney HS (H-7640), chondroitin sulfate
C (C-4384), chondroitin sulfate B (C-3788), chondroitin
sulfate A (C-9819), human recombinant bFGF (F-0291),
and salmon protamine sulfate (P-4020).
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